Stephen Dale - Feb 16, 2023 Form 4 Insider Report for Kura Oncology, Inc. (KURA)

Role
Chief Medical Officer
Signature
Teresa Bair, Attorney-in-fact for Stephen Dale
Stock symbol
KURA
Transactions as of
Feb 16, 2023
Transactions value $
$0
Form type
4
Date filed
2/21/2023, 04:08 PM
Previous filing
Jan 31, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KURA Common Stock Award $0 +23.1K +83.56% $0.00 50.8K Feb 16, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KURA Option to purchase common stock Award $0 +185K $0.00 185K Feb 16, 2023 Common Stock 185K $11.99 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of Restricted Stock Units (RSUs). The RSUs vest in four equal annual installments on 1/26/24, 1/26/25, 1/26/26 and 1/26/27.
F2 This option vests in 48 equal monthly installments commencing on the grant date.